USA flag logo/image

An Official Website of the United States Government

Cell-free Detection of GPCR Signaling in a Nanoscale System

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
76274
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
GM072379
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
INTEGRAL MOLECULAR
3711 MARKET ST Suite 900 PHILADELPHIA, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Cell-free Detection of GPCR Signaling in a Nanoscale System
Agency: HHS
Contract: 2R44GM072379-03
Award Amount: $1,192,925.00
 

Abstract:

DESCRIPTION (provided by applicant): G protein-coupled receptors (GPCRs) are one of the most important families of pharmaceutical targets. However, some of the most desirable types of GPCR drugs have also been some of the most difficult to discover. GPCRs are integral membrane proteins that are traditionally studied in live cells or cell membrane preparations, sources that limit the ability to purify and manipulate GPCR proteins. These limitations have hindered the discovery of drugs against many important GPCRs and drugs with pharmacologically-specific mechanisms of action. A novel method that aids in discovering new and improved GPCR drugs could have a major impact on human health. We have demonstrated the feasibility of a unique assay system for GPCR acti vation that offers the benefits of a cell-based system (relevant signaling pathways) without their drawbacks. Our strategy involves the use of a novel technology, the Lipoparticle that enables structurally-intact GPCRs to be purified away from cells and as sayed for activity. The Specific Aims of our proposal are: I. Test the LipoSignal assay for screening diverse GPCR activators and inhibitors II. Develop the LipoSignal assay to target pharmacologically distinguishable GPCR signaling mechanisms III. Format a LipoSignal Array to identify GPCR cross-reactivity and orphan GPCR-ligand pairs. PUBLIC HEALTH RELEVANCE: The product that results from this proposal will contribute to public health and the cure of human diseases by providing a novel approach for identifying better drugs and new ligands against GPCRs. The chemokines receptors, including CXCR4 and CCR5, are involved in cancer, inflammatory diseases, and HIV infection, and are a major focus of this proposal. However, our technology has broad applica tion to a diverse range of GPCRs, and also has the capability of being used to identify cell- and signaling pathway-specific GPCR drugs that are difficult to identify using conventional assays. As a result of this proposal, we expect to commercialize a pro duct that will lead directly to the development of new and improved GPCR drugs.

Principal Investigator:

Benjamin J. Doranz
2159666018
BDORANZ@INTEGRALMOLECULAR.COM

Business Contact:


bdoranz@integralmolecular.com
Small Business Information at Submission:

INTEGRAL MOLECULAR
INTEGRAL MOLECULAR 3701 MARKET ST, STE 340 PHILADELPHIA, PA 19104

EIN/Tax ID: 233091965
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No